TOKYO, Jun 08 (Pulse News Wire) – 3-D Matrix,ltd. (7777.T) announced today that its drug candidate MIRX002, developed in collaboration with PURMX Therapeutics, has successfully completed a phase I trial targeting malignant pleural mesothelioma patients.
The trial included both single-dose and repeated-dose tests conducted by Professor Okada at Hiroshima University's Institute of Radiation Biology and Medicine. In the single-dose test, nine patients received MIRX002 intrathoracically across three dosage groups. Four patients participated in the repeated-dose test, receiving up to three doses administered every 28 days. Both trials achieved their primary safety and tolerability endpoints without clinically significant side effects, demonstrating the drug’s favorable safety profile.
Additionally, the company noted that MIRX002 leverages its proprietary self-assembling peptide technology known as DDS, which protects microRNAs during delivery and enhances their effectiveness against cancer cells. This breakthrough could expand the application of nucleic acid drugs in various therapeutic areas. There will be no impact on the company’s ongoing fiscal year performance or mid-term business plan revenues due to this development. However, 3-D Matrix stated that it would promptly disclose any potential impacts related to regulatory approval or further clinical developments.
🟢 Confidence: High AI-translated content.